D. Western Therapeutics Institute, Inc.
4576
Rank in Stocks
#26719
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused... D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
Share Price
$0.3228124
Last synced: 2026-11-10
Market Cap
$18.59M
Change (1 day)
2.00%
Change (1 year)
-51.56%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade D. Western Therapeutics Institute, Inc. (4576)
Category
Healthcare
Operating Margin for D. Western Therapeutics Institute, Inc. (4576)
Operating Margin as of November 2026 TTM: -252.02%
According to D. Western Therapeutics Institute, Inc.'s latest financial reports, its current operating margin (TTM) is -252.02%. At the end of 2025 the company had an operating margin of -159.92%.
Operating Margin history for D. Western Therapeutics Institute, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -252.02% | 57.59% |
| 2025 | -159.92% | -37.65% |
| 2024 | -256.50% | 37.59% |
| 2023 | -186.42% | 173.06% |
| 2022 | -68.27% | 64.82% |
| 2021 | -41.42% | -44.57% |
| 2020 | -74.72% | -469.72% |
| 2019 | 20.21% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.15% |
US
|
|
| -149.01% | -99.41% |
US
|
|
| 25.57% | -100.10% |
AU
|
|
| 31.23% | -100.12% |
BE
|
|
| 29.35% | -100.12% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about D. Western Therapeutics Institute, Inc.'s operating margin
What is D. Western Therapeutics Institute, Inc.'s operating margin?
D. Western Therapeutics Institute, Inc.'s operating margin is -252.02%, as of Nov 2026.
What was D. Western Therapeutics Institute, Inc.'s operating margin in 2025?
In 2025, D. Western Therapeutics Institute, Inc.'s operating margin was -159.92%, compared with -256.50% in 2024.
How has D. Western Therapeutics Institute, Inc.'s operating margin changed since 2020?
From 2020 to 2025, D. Western Therapeutics Institute, Inc.'s operating margin was highest in 2021 (-41.42%) and lowest in 2024 (-256.50%).
How does D. Western Therapeutics Institute, Inc.'s operating margin compare with similar companies?
D. Western Therapeutics Institute, Inc.'s operating margin (-252.02%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.